According to the article, a $10,000 investment in Eli Lilly five years ago would be worth about $54,477 today, reflecting a 40.36% average annual return including dividend reinvestment. The same amount invested in an ETF that tracks the S&P 500 would be worth $17,940. Eli Lilly became the first healthcare company to reach a $1 trillion market cap and is a leader in the fast-growing GLP-1 market, with strong sales growth for its key medicines and a deep pipeline. The author does not expect average annual returns of about 40% to continue through 2031, but says the healthcare leader still appears well positioned to beat the broader equity market.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
Eli LillypharmaceuticalsS&P 500ETF
Open a keyword to see other news on the same topic.
Related news
- Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?
The article compares revenue growth at Bristol Myers Squibb and Eli Lilly. Lilly's growth is driven by GLP-1 drugs: Mounjaro brought in $9.9 billion worldwide in Q2 (up 91% year over year), Zepbound $4.9 billion in U.S. sales, and the oral Foundayo, launched in April 2026, $98 million in its first quarter. Bristol Myers Squibb (BMY) has steadier revenue, with no GLP-1 drug on the market and reliance on Eliquis and Opdivo, and its growth portfolio made up 58% of Q2 revenue. The article notes Bristol Myers Squibb trades at about 9.4 times forward earnings versus almost 25 times for Lilly, and says Lilly's two main products account for nearly two-thirds of quarterly sales, a concentration and pricing risk to its growth. Both companies report third-quarter results on Oct. 29.
- Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock?
Novo Nordisk presented a post hoc analysis of a Phase 3 CagriSema trial at The Menopause Society meeting: after 68 weeks, 2,309 women lost almost 25% of body weight on average, versus 3% on placebo. Among 1,902 women with menopause-related overweight or obesity, mean loss ranged from 23% to nearly 27%, while placebo averaged 2%. These results beat or match Wegovy (just under 15%) and Zepbound (nearly 21%), though in the head-to-head Redefine 4 trial, tirzepatide, Zepbound's molecule, showed similar or slightly higher efficacy, nearly 26% at the maximum dose. The author argues CagriSema is unlikely to win back market share from Eli Lilly, so investors should watch Novo's other pipeline programs, and notes the figures assume patients use the drug as directed.
- Eli Lilly, IBD Stock Of The Day, Rides Foundayo, Medicare Bridge To Buy Point
- These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Eli Lilly Leads Industry
- Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher
Eli Lilly's Foundayo, an oral GLP-1 weight-loss medicine approved in the U.S. in April, is drawing new patients, with 80% of its prescriptions earlier this year going to people who had never taken a GLP-1 medicine before. The company's Onswik, a once-weekly basal insulin for diabetes approved in September, could strengthen its diabetes portfolio, though Novo Nordisk's Awiqli was approved first in March. The investigational retatrutide showed average weight loss of up to 28.3% over 80 weeks in one Phase 3 study, and Eli Lilly plans to submit it for regulatory approval in the first quarter of 2027. The article argues these drugs could power Eli Lilly's next phase of growth beyond Zepbound.
- A $1,000 Investment in Eli Lilly Became $18,637. The Obesity Boom Changed Everything
Eli Lilly, once a steady insulin maker, became a major player in obesity drugs after tirzepatide, sold as Mounjaro and Zepbound, reshaped its business. A $1,000 investment ten years ago grew to $18,637 in share price terms, versus $3,634 for the S&P 500 over the same period, though these figures exclude dividends, which rose from $0.51 to $1.73 a quarter. Q2 2026 revenue rose 47.7% to $22.97 billion, and the company raised full-year guidance to $85.0–87.0 billion. Volume growth of 60% has more than offset a 13% fall in realized prices, while Lilly plans a U.S. filing for retatrutide in Q1 2027. The article notes shares fell about 22% between February 4 and April 30, 2026, before recovering.
Related markets
Latest news
- 17,000 troops massed at hotspot, over 100 UAVs target Voronezh: Zelensky makes special offer to Putin
According to Russian media citing TST, Ukraine has massed about 17,000 troops in an area only 25 km wide where Dnipropetrovsk, Zaporizhzhia and Donetsk meet, including airborne and marine brigades and the 3rd Regiment of the Special Operations Forces. Colonel Vladimir Antonyuk said the objectives later shifted to military-tactical targets, namely the transport junctions at Velikaya Novosyolka and Bogatyr, where Russian defenses had been reinforced beforehand. In the night of 25 to 26 October, Voronezh region was hit by over 100 UAVs; Governor Alexander Gusev said more than 70 were shot down around Voronezh city, and two people were killed and 17 injured, including a child. A Russian military expert said Kharkiv region could be a launch area and recalled Putin's order to the military to set up a buffer zone along the border. President Zelensky said Ukraine is ready to discuss a territorial exchange, but on one condition.
- RBC Says SpaceX Stock Has 50% Upside. S&P Global Just Warned About Its Hidden AI Debt. Here's Who I Think Is Right.
RBC reiterated its outperform rating and $225-per-share price target after SpaceX's Oct. 20 earnings, which showed $14.6 billion in revenue (up 161%) and $4.4 billion in earnings, versus a $1.1 billion loss in the year-earlier quarter. Starlink contributed $5.25 billion in revenue and $2.4 billion in operating income, and management guided first-quarter 2027 revenue to $33-37 billion, above the $22 billion Wall Street estimate. S&P Global, in contrast, warned that six top hyperscalers, including SpaceX, plan to spend $7 trillion on AI through 2029, including guarantees that do not appear as debt on balance sheets. SpaceX's AI capex was $19.6 billion last quarter and is estimated at $35-40 billion this quarter, while the company is finalizing a $40 billion off-balance-sheet debt structure. The article concludes that the outcome of this AI bet remains uncertain.
- Savings rates fall to near 0% at one bank
Ngan hang TMCP Sai Gon (SCB) cut its online savings rates for new individual customers to 0.1-0.7% per year from October 26, 2026, well below the system's general level. Deposits of 31, 39 and 45 days and 1 to 5 months earn 0.1% per year, 6 to 11 months 0.5%, 12, 13, 15 and 18 months 0.6%, and 24 and 36 months 0.7%, the highest in the table. For 100 million VND deposited for 12 months at 0.6% per year, interest at maturity is 600,000 VND; for 24 months at 0.7%, estimated interest is 1.4 million VND, assuming the rate holds and no early withdrawal. The move follows an October 21 directive from the State Bank of Vietnam requiring banks to cut average deposit rates by at least 0.5 percentage points per year for new deposits of six months or longer in late 2026. SCB has been under special control since 2022 and has shrunk from nearly 240 transaction points to about 8 across 6 localities.
- The value of audit is measured by positive changes in national governance
National Assembly Chairman Tran Thanh Man received heads of delegations from 16 Supreme Audit Institutions (SAIs) attending an international seminar hosted by the State Audit of Vietnam on October 27, which drew about 250 delegates and 13 papers on institutions, vision and innovation. Insights from the seminar will inform the State Audit's development strategy to 2035, its vision to 2045 and proposed amendments to the State Audit Law. On behalf of the international delegations, K. Sanjay Murthy, Comptroller and Auditor General of India and ASOSAI chair, said audit value lies in recommendations that help agencies fix shortcomings, and that SAIs must adopt AI and data analysis to shift toward early risk warnings. Chairman Tran Thanh Man stressed that independence must go with accountability and that audit value is measured by positive changes in governance.
- Indian investors rush to Nvidia, SpaceX, Apple as local trading apps roll out access to U.S. stocks
Major Indian platforms Groww, Zerodha and Angel One are opening U.S. stock trading to retail investors, previously available mainly to wealthier Indians through global banks. Groww, which accounts for more than 29% of the country's 46 million active investors, offers access to more than 10,000 U.S. stocks, ETFs and fractional shares, with NVIDIA, SpaceX and Apple among the most popular among early users. Demand is driven by Indian underperformance: the Nifty 50 has fallen nearly 13% since the start of the year while the S&P 500 has gained over 12%, and foreign investors have pulled a record $32.5 billion from Indian equities this year. Resident Indians sent over $321 million abroad for equity and debt investment in August, up 111% from a year earlier. Kotak Mahindra's Nitin Jain cautioned that regulators could have second thoughts about retail access to U.S. markets as participation grows.
- Gold bar and gold ring prices on the morning of October 28 at SJC, Bảo Tín Mạnh Hải, DOJI and PNJ
On the morning of October 28, SJC, Bảo Tín Mạnh Hải, DOJI and PNJ all quoted gold bars at 139 million VND per tael to buy and 142 million VND to sell, unchanged from the previous close, while gold rings were quoted between 135 and 141.3 million VND per tael. World gold rebounded on October 27 (U.S. time) as crude oil fell, reaching around 4,058.20 USD per ounce, up 42 USD (1.05%). Gains were capped by a stronger U.S. dollar and the 10-year U.S. Treasury yield near 4.99%. Investors are focused on the Fed's rate decision expected on October 28 (U.S. time), with markets leaning toward the Fed holding rates steady.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.